Chugai Pharmaceutical Past Earnings Performance
Past criteria checks 6/6
Chugai Pharmaceutical has been growing earnings at an average annual rate of 9.1%, while the Pharmaceuticals industry saw earnings growing at 5% annually. Revenues have been growing at an average rate of 5.6% per year. Chugai Pharmaceutical's return on equity is 23.7%, and it has net margins of 35%.
Key information
9.13%
Earnings growth rate
9.11%
EPS growth rate
| Pharmaceuticals Industry Growth | 3.41% |
| Revenue growth rate | 5.59% |
| Return on equity | 23.70% |
| Net Margin | 35.02% |
| Next Earnings Update | 24 Jul 2026 |
Recent past performance updates
Recent updates
Narrative Update • Jun 04
4519: Higher Revenue Outlook And Profitability Assumptions Will Support Bullish 2025 View
Analysts have lifted their fair value estimate for Chugai Pharmaceutical stock from ¥8,571.43 to ¥9,973.33, citing updated assumptions for revenue growth, profit margins, a slightly higher discount rate, and a modestly lower future P/E multiple. What's in the News Chugai Pharmaceutical has scheduled a board meeting for April 24, 2026, to consider and approve the introduction of a trust-based stock compensation system, including decisions on the scale and timing of acquiring the company’s shares.
Narrative Update • May 08
4519: Gene Therapy Rollout Will Drive Long Term Upside Potential
Analysts have trimmed their price target for Chugai Pharmaceutical from ¥13,297 to ¥12,801. This reflects updated assumptions for slightly higher revenue growth, a modestly lower profit margin, and a small change in the projected P/E multiple and discount rate.Analysis Article • Apr 28
Chugai Pharmaceutical Co., Ltd. (TSE:4519) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
As you might know, Chugai Pharmaceutical Co., Ltd. ( TSE:4519 ) just kicked off its latest first-quarter results with...Narrative Update • Apr 21
4519: Gene Therapy Launch And Rising Dividends Will Drive Future Upside Potential
Analysts have made a small trim to the fair value estimate for Chugai Pharmaceutical, adjusting the price target from ¥13,300 to about ¥13,297 as they balance slightly revised assumptions for revenue growth, profit margins and future P/E multiples. What's in the News Roche decided to discontinue clinical development of GYM329 (emugrobart) for spinal muscular atrophy and facioscapulohumeral muscular dystrophy after Phase II and Phase II/III data did not show consistent, robust functional benefits, while safety remained acceptable (Key Developments).
Narrative Update • Apr 07
4519: Rich P/E And Trial Setbacks Will Likely Restrain Future Upside
Analysts kept the fair value estimate for Chugai Pharmaceutical steady at ¥6,400. The unchanged price target is supported by updated assumptions that include revenue growth of 4.75%, a profit margin of 38.11% and a future P/E of 22.01x.Narrative Update • Mar 24
4519: Rich P/E And Clinical Setbacks Will Likely Restrain Future Upside
Analysts have nudged their price target for Chugai Pharmaceutical down from ¥6,584.94 to ¥6,400. This change reflects updated assumptions for revenue growth, profit margins and a slightly lower future P/E multiple.Narrative Update • Mar 09
4519: Gene Therapy Launch And Rising Dividends Will Support Future Upside Potential
Analysts have raised their price target for Chugai Pharmaceutical from ¥12,406 to ¥13,300, citing updated assumptions related to slightly higher revenue growth, profit margins and future P/E levels. What's in the News Chugai has launched ELEVIDYS, a gene therapy for Duchenne muscular dystrophy, in Japan after its listing on the National Health Insurance price list.Narrative Update • Feb 23
4519: Rising Dividend Commitment Will Support Future Upside Potential
Analysts have raised their price target on Chugai Pharmaceutical from ¥10,728 to ¥12,406, citing updated assumptions that include adjusted discount rates, revenue growth, profit margins and future P/E levels. What's in the News Chugai Pharmaceutical plans annual dividends of ¥132 per share for the fiscal year ending December 31, 2026, with interim dividends of ¥66 and an expected Core dividend payout ratio of 44.7% for 2026, or 54.7% on a five year average basis (Key Developments).Narrative Update • Feb 09
4519: Rising Dividends And Rich P/E Will Likely Limit Future Upside
Analysts have nudged their price target on Chugai Pharmaceutical to ¥6,584.94 from ¥6,400, citing updated assumptions around a slightly higher discount rate, modestly adjusted revenue growth, a marginally stronger profit margin, and a higher future P/E multiple. What's in the News The board will meet on January 29, 2026 to propose a dividend of retained earnings, with a record date of December 31, 2025, to the 115th Annual General Meeting of Shareholders on March 26, 2026, and to consider other business items (Key Developments).Analysis Article • Feb 01
Chugai Pharmaceutical Co., Ltd. (TSE:4519) Yearly Results Just Came Out: Here's What Analysts Are Forecasting For This Year
The yearly results for Chugai Pharmaceutical Co., Ltd. ( TSE:4519 ) were released last week, making it a good time to...Narrative Update • Jan 26
4519: Renalys Merger Execution Will Likely Cap Future Share Upside
Analysts have maintained their price target for Chugai Pharmaceutical at ¥6,400, citing only minor adjustments to revenue growth, profit margin and future P/E assumptions that do not materially change their overall view of the shares. What's in the News Board meeting scheduled for November 18, 2025, to review an absorption-type merger with Renalys Pharma, Inc.Analysis Article • Jan 14
A Look At The Intrinsic Value Of Chugai Pharmaceutical Co., Ltd. (TSE:4519)
Key Insights Chugai Pharmaceutical's estimated fair value is JP¥7,735 based on 2 Stage Free Cash Flow to Equity With...Narrative Update • Jan 11
4519: Renalys Acquisition And Merger Execution Risks Will Likely Limit Upside
Analysts have kept their price target for Chugai Pharmaceutical steady at ¥6,400, citing slightly more conservative revenue growth expectations, along with a small uplift in projected profit margins and a marginally higher future P/E multiple. What's in the News A board meeting is scheduled for October 24, 2025, to consider acquiring all shares and stock acquisition rights of Renalys Pharma, a domestic bioventure company, and to consider obtaining exclusive development and commercialization rights in Japan, South Korea, and Taiwan for sparsentan, which is being developed mainly for IgA nephropathy (Key Developments).Narrative Update • Dec 27
4519: Rising Execution And Merger Risks Will Likely Cap Medium-Term Upside
Narrative Update Analysts have raised their price target on Chugai Pharmaceutical from ¥6,100 to ¥6,400, citing stronger medium term revenue growth expectations, slightly higher margins, and a modestly lower anticipated future P E multiple. What's in the News Board meeting scheduled for November 18, 2025, to approve an absorption-type merger with Renalys Pharma, following its planned acquisition as a wholly owned subsidiary on November 27, 2025 (Board Meeting) Board meeting on October 24, 2025, to decide on acquiring all shares and stock acquisition rights of Renalys Pharma, securing exclusive development and commercialization rights in Japan, South Korea, and Taiwan for sparsentan for IgA nephropathy (Board Meeting) Collaboration and license agreement with Rani Therapeutics to develop an oral rare disease antibody product using RaniPill technology, with up to $1.085 billion in potential deal value including milestones and royalties (Client Announcements) Upcoming sustainability-focused Analyst and Investor Day, highlighting non-financial and ESG-related priorities (Analyst/Investor Day) Valuation Changes Fair Value: Increased slightly from ¥6,100 to ¥6,400, reflecting a modestly higher fundamental valuation.Narrative Update • Dec 13
4519: Merger And Renal Portfolio Expansion Will Shape Balanced Outlook In 2025
Analysts have nudged their price target on Chugai Pharmaceutical slightly higher to approximately ¥8,571 from about ¥8,525, reflecting greater confidence in the company’s revenue growth trajectory despite only marginal shifts in long term margin and valuation assumptions. What's in the News Board approves plan to acquire all shares and stock acquisition rights of Renalys Pharma, securing exclusive rights in Japan, South Korea, and Taiwan to develop and commercialize sparsentan for IgA nephropathy and related indications (Board Meeting, Oct 24, 2025) Upcoming board meeting is set to endorse an absorption type merger with Renalys Pharma following its planned acquisition as a wholly owned subsidiary, consolidating renal disease assets under Chugai (Board Meeting, Nov 18, 2025) Chugai enters a collaboration and license agreement with Rani Therapeutics to combine the RaniPill oral delivery platform with Chugai’s rare disease antibody, with potential deal value up to $1.085 billion across up to six targets (Client Announcements) Positive Phase 3 ACHIEVE 3 topline results for orforglipron, co developed with Eli Lilly, report superior HbA1c reduction and weight loss versus oral semaglutide in adults with type 2 diabetes, adding to Chugai’s metabolic disease portfolio (Product Related Announcements) Chugai schedules a sustainability focused analyst and investor day, reflecting an ongoing emphasis on ESG themes in capital markets communication (Analyst/Investor Day) Valuation Changes Fair Value Estimate nudged higher from approximately ¥8,525 to about ¥8,571, reflecting a modest upward revision in intrinsic valuation.Analysis Article • Dec 01
Chugai Pharmaceutical's (TSE:4519) Dividend Will Be ¥125.00
Chugai Pharmaceutical Co., Ltd. ( TSE:4519 ) has announced that it will pay a dividend of ¥125.00 per share on the 30th...Narrative Update • Nov 28
4519: Absorption-Type Merger And New Collaboration Will Shape Outlook In 2025
Analysts have raised their fair value estimate for Chugai Pharmaceutical from ¥8,339 to ¥8,525. They cite modest improvements in projected revenue growth and updated expectations for the company's financial performance.Analysis Article • Nov 26
Chugai Pharmaceutical Co., Ltd. (TSE:4519) Stocks Shoot Up 26% But Its P/E Still Looks Reasonable
Despite an already strong run, Chugai Pharmaceutical Co., Ltd. ( TSE:4519 ) shares have been powering on, with a gain...Narrative Update • Nov 14
4519: Upcoming Acquisition Decision And Collaboration Will Shape Company Outlook
Analysts have raised their price target for Chugai Pharmaceutical from ¥8,171 to ¥8,339, citing modest improvements in projected revenue growth and profit margin, which support a slightly higher valuation. What's in the News Chugai Pharmaceutical announced a Board Meeting on October 24, 2025 to discuss acquiring all shares and stock acquisition rights of Renalys Pharma, Inc., as well as securing exclusive development and commercialization rights for sparsentan in Japan, South Korea, and Taiwan (Board Meeting).Analysis Article • Oct 29
Chugai Pharmaceutical (TSE:4519) Has Announced A Dividend Of ¥125.00
The board of Chugai Pharmaceutical Co., Ltd. ( TSE:4519 ) has announced that it will pay a dividend on the 30th of...Analysis Article • Oct 28
Chugai Pharmaceutical Co., Ltd. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Shareholders might have noticed that Chugai Pharmaceutical Co., Ltd. ( TSE:4519 ) filed its third-quarter result this...Narrative Update • Oct 15
Roche Collaboration And Biologics Pipeline Will Expand Healthcare Reach
Analysts have slightly raised their price target for Chugai Pharmaceutical from ¥8,082 to ¥8,171, citing improved outlooks for revenue growth and profit margins. What's in the News Chugai Pharmaceutical and Eli Lilly announced positive Phase 3 results from the ACHIEVE-3 trial, showing orforglipron delivered superior improvements in glycemic control and weight loss for adults with type 2 diabetes compared to oral semaglutide.Analysis Article • Oct 13
Chugai Pharmaceutical's (TSE:4519) Dividend Will Be ¥125.00
The board of Chugai Pharmaceutical Co., Ltd. ( TSE:4519 ) has announced that it will pay a dividend on the 30th of...Analysis Article • Sep 29
Chugai Pharmaceutical's (TSE:4519) Dividend Will Be ¥125.00
The board of Chugai Pharmaceutical Co., Ltd. ( TSE:4519 ) has announced that it will pay a dividend on the 30th of...Analysis Article • Sep 15
Chugai Pharmaceutical's (TSE:4519) Dividend Will Be ¥125.00
Chugai Pharmaceutical Co., Ltd.'s ( TSE:4519 ) investors are due to receive a payment of ¥125.00 per share on 30th of...Narrative Update • Sep 05
Roche Collaboration And Biologics Pipeline Will Expand Healthcare Reach
Given the lack of material changes in both Chugai Pharmaceutical's revenue growth forecasts and future P/E ratio, analysts have maintained their consensus price target at ¥8,082. What's in the News Orforglipron, an investigational GLP-1 receptor agonist, achieved positive topline results in two Phase 3 trials (ATTAIN-1 and ATTAIN-2), demonstrating significant weight loss, HbA1c reduction, and improvements in cardiometabolic risk factors, with a safety profile consistent with its drug class.Analysis Article • Aug 31
Chugai Pharmaceutical (TSE:4519) Will Pay A Dividend Of ¥125.00
Chugai Pharmaceutical Co., Ltd. ( TSE:4519 ) has announced that it will pay a dividend of ¥125.00 per share on the 30th...Analysis Article • Aug 17
Chugai Pharmaceutical Co., Ltd.'s (TSE:4519) Shareholders Might Be Looking For Exit
With a price-to-earnings (or "P/E") ratio of 26x Chugai Pharmaceutical Co., Ltd. ( TSE:4519 ) may be sending very...Analysis Article • Jul 26
Chugai Pharmaceutical Co., Ltd. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
It's been a good week for Chugai Pharmaceutical Co., Ltd. ( TSE:4519 ) shareholders, because the company has just...Analysis Article • Jul 10
If EPS Growth Is Important To You, Chugai Pharmaceutical (TSE:4519) Presents An Opportunity
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
New Narrative • Mar 09
Accelerating RED Capabilities And Robust Pipeline Will Enhance Future Prospects
Emphasis on RED capabilities and innovative products aims to drive revenue growth and improve net and operating margins.Revenue & Expenses Breakdown
Revenue & Expenses Breakdown
How Chugai Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 26 | 1,291,229 | 452,196 | 122,125 | 188,558 |
| 31 Dec 25 | 1,257,941 | 434,012 | 116,461 | 187,598 |
| 30 Sep 25 | 1,213,713 | 397,161 | 111,954 | 187,420 |
| 30 Jun 25 | 1,196,214 | 395,444 | 111,845 | 183,739 |
| 31 Mar 25 | 1,222,121 | 410,150 | 110,749 | 181,012 |
| 31 Dec 24 | 1,170,611 | 387,317 | 110,098 | 181,440 |
| 30 Sep 24 | 1,142,350 | 386,964 | 108,439 | 171,068 |
| 30 Jun 24 | 1,084,570 | 355,041 | 108,201 | 171,722 |
| 31 Mar 24 | 1,036,076 | 326,373 | 114,150 | 173,356 |
| 31 Dec 23 | 1,111,367 | 325,472 | 112,580 | 174,868 |
| 30 Sep 23 | 1,276,051 | 336,745 | 112,702 | 178,244 |
| 30 Jun 23 | 1,243,437 | 326,969 | 107,753 | 169,379 |
| 31 Mar 23 | 1,211,632 | 316,154 | 96,519 | 158,627 |
| 31 Dec 22 | 1,259,946 | 374,429 | 100,760 | 149,626 |
| 30 Sep 22 | 1,143,716 | 370,791 | 104,720 | 142,201 |
| 30 Jun 22 | 1,205,696 | 389,011 | 106,839 | 141,695 |
| 31 Mar 22 | 1,191,496 | 387,359 | 107,887 | 141,438 |
| 31 Dec 21 | 999,759 | 302,995 | 102,416 | 137,299 |
| 30 Sep 21 | 887,919 | 256,462 | 98,992 | 132,324 |
| 30 Jun 21 | 809,055 | 230,577 | 96,489 | 126,265 |
| 31 Mar 21 | 776,339 | 210,611 | 94,546 | 121,477 |
| 31 Dec 20 | 786,946 | 214,733 | 94,401 | 117,850 |
| 30 Sep 20 | 753,853 | 202,590 | 95,497 | 116,049 |
| 30 Jun 20 | 734,019 | 190,599 | 96,919 | 110,994 |
| 31 Mar 20 | 711,320 | 174,062 | 102,068 | 108,903 |
| 31 Dec 19 | 686,184 | 157,560 | 101,574 | 107,942 |
| 30 Sep 19 | 662,198 | 139,543 | 99,844 | 105,231 |
| 30 Jun 19 | 614,949 | 113,070 | 97,895 | 102,491 |
| 31 Mar 19 | 586,648 | 99,631 | 92,379 | 99,289 |
| 31 Dec 18 | 579,787 | 92,488 | 93,416 | 99,202 |
| 30 Sep 18 | 572,994 | 85,857 | 91,553 | 98,150 |
| 30 Jun 18 | 566,548 | 85,285 | 89,710 | 96,639 |
| 31 Mar 18 | 556,159 | 82,101 | 89,631 | 98,744 |
| 31 Dec 17 | 534,199 | 72,713 | 88,147 | 92,947 |
| 30 Sep 17 | 517,908 | 67,704 | 82,411 | 90,427 |
| 30 Jun 17 | 497,023 | 58,143 | 82,465 | 89,728 |
| 31 Mar 17 | 497,354 | 57,592 | 81,248 | 85,000 |
| 31 Dec 16 | 491,780 | 53,592 | 81,941 | 85,011 |
| 30 Sep 16 | 492,584 | 56,562 | 85,481 | 83,366 |
| 30 Jun 16 | 506,192 | 62,537 | 86,313 | 84,761 |
| 31 Mar 16 | 501,649 | 61,043 | 87,772 | 84,111 |
| 31 Dec 15 | 498,839 | 61,125 | 88,018 | 83,799 |
| 30 Sep 15 | 495,455 | 58,897 | 85,492 | 85,815 |
| 30 Jun 15 | 479,265 | 52,220 | 86,648 | 83,082 |
Quality Earnings: 4519 has high quality earnings.
Growing Profit Margin: 4519's current net profit margins (35%) are higher than last year (33.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4519's earnings have grown by 9.1% per year over the past 5 years.
Accelerating Growth: 4519's earnings growth over the past year (10.3%) exceeds its 5-year average (9.1% per year).
Earnings vs Industry: 4519 earnings growth over the past year (10.3%) exceeded the Pharmaceuticals industry 6.8%.
Return on Equity
High ROE: 4519's Return on Equity (23.7%) is considered high.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/16 22:54 |
| End of Day Share Price | 2026/06/16 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Chugai Pharmaceutical Co., Ltd. is covered by 27 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Atsushi Seki | Barclays |
| Miki Sogi | Bernstein |
| Koichi Mamegano | BofA Global Research |